VANDA PHARMACEUTICALS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
VANDA PHARMACEUTICALS INC. - More news...
VANDA PHARMACEUTICALS INC. - More news...
- Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
- Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
- Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN
- Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences
- Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results
- Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021
- Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day
- Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference
- Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients
- Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results
- Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021
- Vanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor Conferences
- Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results
- Vanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
- VANDA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Vanda Pharmaceuticals Inc. - VNDA
- Thinking about buying stock in Sundial Growers, Diffusion Pharmaceuticals, Vanda Pharmaceuticals, Aurora Cannabis, or Globalstar?
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021
- FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
- Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
- Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
- Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
- Vanda Pharmaceuticals Provides Update on Tradipitant Development Program
- Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
- Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
- FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
- Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
- FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
